Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Gross Margin (2020 - 2026)

Bioventus filings provide 6 years of Gross Margin readings, the most recent being 68.89% for Q4 2025.

  • On a quarterly basis, Gross Margin rose 208.0% to 68.89% in Q4 2025 year-over-year; TTM through Dec 2025 was 68.33%, a 61.0% increase, with the full-year FY2025 number at 68.33%, up 61.0% from a year prior.
  • Gross Margin hit 68.89% in Q4 2025 for Bioventus, up from 67.96% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 72.83% in Q2 2021 to a low of 58.96% in Q4 2022.
  • Median Gross Margin over the past 5 years was 67.31% (2021), compared with a mean of 67.02%.
  • Biggest five-year swings in Gross Margin: crashed -834bps in 2022 and later surged 618bps in 2024.
  • Bioventus' Gross Margin stood at 67.3% in 2021, then decreased by -12bps to 58.96% in 2022, then rose by 8bps to 63.73% in 2023, then increased by 5bps to 66.82% in 2024, then rose by 3bps to 68.89% in 2025.
  • The last three reported values for Gross Margin were 68.89% (Q4 2025), 67.96% (Q3 2025), and 69.14% (Q2 2025) per Business Quant data.